Breo Ellipta: what it treats, how to use it, side effects
Last updated September 3, 2026.
Breo Ellipta pairs an inhaled corticosteroid (fluticasone furoate) with a long-acting bronchodilator (vilanterol, a LABA) in one once-daily inhaler. Approved for COPD maintenance and asthma (ages 5 and up), it was the first once-daily ICS/LABA, and once-daily is its whole pitch: one inhalation, same time every day.
What does it treat?
Maintenance treatment of COPD (100/25 mcg strength) and of asthma in patients 5 and older (100/25 or 200/25 mcg in adults; the lower strength in children). Maintenance is the load-bearing word: it prevents symptoms and exacerbations over time and is explicitly not for acute bronchospasm. Your rescue inhaler stays yours.
How do you take it?
One inhalation once daily, at the same time every day, and never more than one in 24 hours. The Ellipta device counts down doses: slide the cover until it clicks (that loads the dose), breathe out away from the device, then inhale long, steady, and deep through the mouthpiece, hold, and breathe out slowly. Rinse your mouth with water and spit after every dose; that single habit prevents most of the oral thrush that inhaled steroids cause. Missed dose: inhale when remembered unless the next dose is near; never double up. Do not stop it because you feel fine; feeling fine is the drug working.
Side effects to know
- Common: colds and upper-respiratory infections, headache, oral thrush, hoarseness, back pain, and in COPD patients a higher pneumonia rate, the known ICS trade-off.
- Serious: the LABA class warning (LABAs alone increase asthma-related death, which is why vilanterol is never used without the steroid in asthma), paradoxical bronchospasm, adrenal suppression at high doses, bone-density loss, glaucoma and cataracts with long use, and immune suppression around infections like chickenpox or measles.
Who should not take it?
Not as a rescue inhaler, and not with a severe milk-protein allergy (the powder contains lactose). Strong CYP3A4 inhibitors like ketoconazole and ritonavir raise steroid exposure. Heart rhythm problems, high blood pressure, thyroid overactivity, seizures, osteoporosis, and eye disease all belong on the prescriber's radar. In asthma it is always the combination; LABA-only inhalers are a different, riskier story.
When is it an emergency?
Call 911 if breathing worsens immediately after a dose (paradoxical bronchospasm), for facial swelling or trouble breathing, or if your rescue inhaler stops working during an attack. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
Is Breo a rescue inhaler?
No, and the label says so plainly: not for acute bronchospasm. It works over days to weeks reducing inflammation and holding airways open in the background. Your albuterol (or similar) rescue inhaler is for attacks; Breo is for making attacks rarer. Using Breo during an attack does nothing fast.
Why once daily when other inhalers are twice?
Both components, fluticasone furoate and vilanterol, are engineered for 24-hour duration, so one inhalation covers the day. That is a genuine adherence advantage: every missed dose of a twice-daily inhaler is a half-day unprotected, while once-daily dosing halves the opportunities to forget.
Why do I have to rinse my mouth after?
The steroid deposits in the mouth and throat on every puff, and left there it feeds a yeast overgrowth (oral thrush) and causes hoarseness. Rinse, gargle, spit, never swallow, and you prevent most of it. White patches or soreness that show up anyway are treatable; report them rather than quitting the inhaler.
What is the LABA warning about?
Years ago, long-acting beta-agonists used alone in asthma were linked to increased asthma deaths, and the class carries that boxed warning still. The resolution is the combination: LABAs in asthma are only used welded to an inhaled steroid, as in Breo, where the steroid treats the inflammation the LABA does not touch.
I have COPD. Does the steroid in Breo raise pneumonia risk?
Yes, modestly: inhaled corticosteroids in COPD carry a known increased pneumonia rate, which is why guidelines steer frequent exacerbators with high eosinophils toward ICS-containing regimens and others toward LABA/LAMA combinations. Your exacerbation history is what justifies the steroid component; your team weighs it against that risk.
How will I know it is working?
Not by feel on day one. Markers over 2 to 8 weeks: fewer rescue-inhaler uses, less night waking, easier stairs, and no exacerbations stacking up. Spirometry at follow-up gives the objective read. If nothing moves after a couple of months, the inhaler technique gets checked first and the regimen second.